NR4A3 Fusion

CI-VAR-00001456Explore in graph →CIViC 5115

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acinar Cell Carcinoma4
v::NR4A3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID12336 In this 2022 study the authors included 4 cases of sinonasal acinic cell carcinoma and 10 acinic cell carcinoma cases of the parotid gland. All four sinonasal patients were male, aged from 27 to 70 ye… (full text at CIViC) PMID 34873305 · Wang et al., 2022 · Open in CIViC	civic
v::NR4A3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12816 In this 2023 study, the authors evaluated the diagnostic utility of NR4A3 immunohistochemistry in acinic cell carcinoma (AciCC) of the salivary gland. The cohort included 128 AciCCs, comprising 85 cla… (full text at CIViC) PMID 36469101 · Klubíčková et al., 2023 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.